New Study Shows Urinary Levels Of Novel Biomarkers Measured By Astute Medical's NephroCheck® Test Are Associated With Adverse Long-term Outcomes In Patients With Acute Kidney Injury
January 13, 2015New study shows novel biomarkers measured by Astute Medical's NephroCheck® Test are associated with adverse long-term outcomes in acute kidney injury (AKI). Clinical studies of the NephroCheck® Test continue to yield new information about AKI biomarkers.
More »
CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred Stock Offering
January 13, 2015CoLucid Pharmaceuticals completes a $37.1 million Series C preferred stock offering. All of the Company’s existing investors participated, including Domain Associates. Proceeds will be used to fund its Phase 3 program to treat migraines.
More »
Aldeyra Therapeutics Announces $7.79 Million Private Placement
January 13, 2015Aldeyra Therapeutics enters into a definitive purchase agreement to raise $7.79 million in private placement of common stock and warrants. Proceeds will go toward its upcoming Phase 2 clinical trials in Sjögren-Larsson Syndrome (SLS).
More »